Figure 5: EBF1 interacts with TET2 at hypermethylated loci.
From: Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2

(a) ChIP-qPCR analysis at three target sites shows proportional presence of both TET2 and EBF1 at these loci. Fold enrichments were calculated by ΔΔCt, normalising to both the mock IgG IP control and a negative control region where no binding of either protein was expected. Error bars correspond to standard errors of the mean, n=3. (b) Motif logo matching between CDGGRA (bottom) and the consensus EBF1 motif (top), as determined by TOMTOM (MEME). The offset of the sequence relative to the known motif was used in conjunction with the nucleotide frequencies in each motif to determine the significance of the match: TOMTOM P-value=0.00249671. (c) Endogenous EBF1 interacts with TET2 in SW1353 cells. Western blotting of anti-TET2 and control IgG immuno-complexes with indicated antibodies. A longer exposure of input lysates (5% of total) is indicated by an asterisk *.